Cargando…
Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials
BACKGROUND: Hyperprolactinemia (HPL) is a common side effect of antipsychotic medications. Recent reports suggest that aripiprazole can ameliorate antipsychotic-induced HPL, but results are inconsistent and the single available systematic review only considered five studies. AIM: Conduct an updated...
Autores principales: | MENG, Meiling, LI, Wei, ZHANG, Shaowei, WANG, Hongyan, SHENG, Jianhua, WANG, Jijun, LI, Chunbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shanghai Municipal Bureau of Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372756/ https://www.ncbi.nlm.nih.gov/pubmed/25852251 http://dx.doi.org/10.11919/j.issn.1002-0829.215014 |
Ejemplares similares
-
Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole
por: Kotorki, Paraskevi, et al.
Publicado: (2010) -
Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia
por: Raveendranthan, Dhanya, et al.
Publicado: (2018) -
Adjunctive Aripiprazole Versus Placebo for Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Randomized Controlled Trials
por: Li, Xianbin, et al.
Publicado: (2013) -
Efficacy and safety of treating patients with refractory
schizophrenia with antipsychotic medication and adjunctive
electroconvulsive therapy: a systematic review and meta-analysis
por: WANG, Wenzheng, et al.
Publicado: (2015) -
Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia: A systematic review
por: Cui, Huiru, et al.
Publicado: (2012)